Investor Overview Press Releases November 13, 2023 Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update November 6, 2023 Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update October 3, 2023 Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202) View all » Events Nov 13, 20238:00 AM EST Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Sep 26, 202310:30 AM EDT Aclaris Therapeutics at 2023 Cantor Global Healthcare Conference Jun 14, 20234:40 PM PDT Aclaris Therapeutics at 44th Annual Goldman Sachs Healthcare Conference View all » Feature Presentation Aclaris Therapeutics Presents ATI-450 Phase 2b Rheumatoid Arthritis Data
November 13, 2023 Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
November 6, 2023 Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
October 3, 2023 Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Nov 13, 20238:00 AM EST Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results